ArticleBMC global and public health2025
Cervical cancer screening data from the case-based national electronic registry in Bangladesh.
Article in BMC global and public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Readiness to transition to HPV self-collection from VIA screening: a mixed methods health systems assessment from Tamil Nadu, India.BMC health services research · 2025Article
- Evaluation of an intelligent digital platform for population management in cervical cancer screening.Cancer biology & medicine · 2025Observational
- Evidence on global public health cancer strategies.BMC global and public health · 2025Article
- High-risk human papillomavirus genotypes among women of hill districts in Bangladesh.PloS one · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe Government of Bangladesh established a visual inspection with acetic acid (VIA)-based cervical cancer screening programme at 600 primary, secondary and tertiary health facilities following a pilot programme in 2005. An aggregated data collection system was initiated using District Health Information System 2 (DHIS2) software in 2013 and a case-based electronic data registry system was developed utilising its "tracker" component since January 2018. The purpose of this study is to review the cervical cancer surveillance situation based on the data of the national cervical cancer screening, treatment and follow-up through the DHIS2-based electronic registry.
methodsWomen aged 30 to 60 were enrolled in the DHIS2 electronic registry in health facilities of all tiers including the community clinics and screened for cervical cancer using the VIA method at Upazila Health Complexes and upper tiers. The VIA-positive women were referred for colposcopy in the nearest colposcopy centres. The screen-positive women were offered treatment and followed up at certain intervals following the national standard protocol. During each encounter, required data were captured in DHIS2. Anonymised data from the DHIS2 covering January 2018 to May 2023 were extracted and analysed for this study.
resultsA total of 1,562,963 women were enrolled in 497 screening facilities and 6398 community clinics. Among them, 1,557,002 (99.6%) availed VIA tests, and primary health facilities performed 74.4% enrolments and 72% VIA tests. Among screened women, 51,913 (3.3%) were VIA positive, of which only 20,954 (40.4%) attended for colposcopy. Among colposcopy-positive women, 6.3% (1,327) and 6.2% (1,302) women had cervical intraepithelial neoplasia (CIN) II/III and cervical carcinoma, respectively. Among women who received treatment for cervical precancer, 81.6% (5062) had thermal ablation, and 17.6% (1089) had loop electrosurgical excision procedure. Histopathology reports (n = 3079) revealed 16.1% (n = 495) of women had squamous cell carcinoma, 4.0% (n = 123) had micro-invasive squamous cell carcinoma, 11.7% (n = 36) had CIN II, and 8.1% (n = 250) had CIN III.
conclusionsThe National Cervical Cancer Screening and Treatment Programme for women in Bangladesh using a DHIS2-based electronic case-based tracking system is effective in understanding the screening situation and can be a valuable lesson for other countries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.